Latest Global Top 100 Medical Device Companies Unveiled (With Detailed List)

Recently,Recently, an authoritative third-party website abroadQMEDThe “2019 Top 100 Medical Device Companies” list has been newly released, ranking global medical device companies based on their 2019 revenue performance.Authoritative Third-Party Websites AbroadQMEDThe “2019 Top 100 Medical Device Companies” list has been newly released, ranking global medical device companies based on their 2019 revenue performance.

According to statistics, thisTop 10the total revenue of the medical device company reached$194.428 billion, globally there are a total of51Revenue of Medical Device CompaniesOver $1 billion. Furthermore, changes in the rankings of the world’s top medical device companies also reflect shifts in the competitive landscape of the medical device industry in 2019.

↓Latest 2019 Top 100 Ranking of Medical Device Companies↓

(Revenue in millions of U.S. dollars)

According to the rankings, Medtronic remains firmly in the top spot, ranking first with $30.891 billion.

Compared to the 2018 list of the top 100 companies by annual revenue, there have been significant changes among the top 10 enterprises in the first tier of global medical device companies.

In the 2019 list of the Top 10 Global Medical Device Companies,Medtronic, Johnson & Johnson, GE, FreseniusThe rankings are consistent with those of 2018, and it is noteworthy thatAbbott, BD...rankings have all risen significantly.

As one of the world's largest orthopedic medical device companies,StrykerPrimarily engaged in the development, manufacturing, and sales of medical products. The company’s product portfolio includes implants for joint replacement and trauma surgery; surgical instruments and surgical navigation systems; endoscopes and communication systems; patient management and emergency medical equipment; neurosurgical, neural, and spinal devices; as well as other medical devices for various medical specialties.

According to the latest financial report,Stryker’s total revenue in 2019 was $14.884 billion, a year-on-year increase of 9.43%.. All business segments demonstrated stable growth, with the orthopedics business increasing by 5.2% year-over-year, medical surgical operations rising by 8.8% year-over-year, and the neuro-spinal business experiencing rapid growth, up 19.2% compared to the previous year.

In mid-2019, Stryker accelerated its acquisition pace, rapidly entering the intraoperative spinal imaging field through the acquisitions of mobile diagnostic imaging company Mobius Imaging and Cardan Robotics, a provider of interventional radiology robotic navigation systems. This move also directly spurred rapid growth in its neurospinal business. Furthermore, Stryker continued to strategically expand its footprint in orthopedics and minimally invasive surgery, making significant acquisitions of OrthoSpace and Wright Medical Group.

2019,Philips’ total revenue was $14.606 billion, a year-on-year increase of 9%.Qixia’s two core medical businesses both saw slight growth, with the Diagnosis and Treatment Department increasing by 10% year-on-year and the Joint Insurance Department rising by 8% year-on-year.

It is reported that in 2020, Philips will focus on developing precision diagnosis and image-guided minimally invasive solutions, as well as patient care solutions spanning both inside and outside the hospital.

As the leading player among the "Big Three" in U.S. pharmaceutical and medical device distribution, it officially updated its Chinese brand name to "Cardinal Health" in China in March 2019.

It has been four years since Cardinal Health acquired Johnson & Johnson’s Cordis business for $1.94 billion, yet the company continues to grapple withManufacturers of Stents, Balloons, and Other Interventional Cardiology ProductsRelated challenges.

In August 2019, Cardinal Health CEO Mike Kaufmann revealed during a conference call that “Cardinal Health has introduced a new sales structure for its medical business and is undergoing a lengthy process to transform its manufacturing, supply chain, and data capabilities. In 2019, Cardinal Health’s focus remained centered onProduct Acquisition Execution and Mergers & Acquisitions。

Currently, Gardano’s 2019 financial report has not yet been released, and its business growth situation remains unclear.

Siemens Healthineers is a leading manufacturer of medical imaging systems, including computed tomography (CT), magnetic resonance imaging (MRI), molecular imaging, X-ray, and ultrasound. The company also produces angiography systems for image-guided therapy, mobile C-arms, and hybrid operating rooms, as well as diagnostic testing systems. Other services include software and clinical consulting.

According to the financial report,Siemens' total revenue in 2019 was $16.09 billion, a year-on-year increase of 8%.Qixia Imaging Business Grew by 10%, Diagnostic Business by 4%, and Clinical Treatment Business by 9%。

In mid-2019, Siemens successively acquired Corindus, a global technology leader in robot-assisted vascular interventions in the United States, and ECG, a U.S. healthcare consulting firm, thereby strengthening its clinical diagnosis and treatment business as well as its medical services.

BD is one of the world’s largest medical technology companies engaged in the research and development, manufacturing, and sales of medical devices, medical systems, and reagents, with a focus on improving drug delivery, enhancing the quality and speed of infectious disease and cancer diagnostics, and advancing the research, development, and production of novel drugs and vaccines.

In its 2019 financial report, BD reported total revenue of $17.29 billion, an 8% year-over-year increase.. In the Qixia business segment, the life sciences business experienced a slight decline, dropping 0.7% year-on-year, while the other medical divisions and the interventional division grew by 5.2% and 29.3%, respectively.

Fresenius Medical Care is the world’s largest medical device company in the field of chronic kidney disease care, providing dialysis products and services to more than 300,000 patients globally. The company has become a leader in the global dialysis market.

The most significant news regarding Fresenius is that in February this year, the U.S. Federal Trade Commission approved the merger between Germany-based Fresenius and U.S. home dialysis equipment manufacturer NxStage Medical Inc. The U.S. Federal Trade Commission stated that,To secure approval for the $2 billion deal, the two companies agreed to divest NxStage’s bloodline tubing set business.

In July 2019, the company’s stock suffered a severe setback amid news that the Trump administration planned to overhaul the kidney care market in an effort to reduce the federal government’s annual $100 billion expenditure on kidney care. The strategy involved new payment models introduced by the U.S. Department of Health and Human Services (HHS), aimed at shifting patients from Fresenius Medical Care’s hemodialysis clinics to home-based treatment. Additionally, HHS planned to enhance prevention and screening efforts for kidney disease.

GE Healthcare Has Yet to Go Public as an Independent Listed Company After a Turbulent Year.

In the 2019 annual report,GE's Annual Revenue Reaches $19.942 Billion, a 1% Year-on-Year Increase. It is reported that Kieran Murphy, President and CEO of GE Healthcare, stated that the company’s current primary focus is to invest resources in collaborations with next-generation companies, aiming to transform how physicians work and achieve more precise patient care.

2019,Abbott Achieves Total Revenue of $19.952 Billion, a 6% Year-over-Year Increase. Surging from 11th place in 2018 to 3rd place, primarily driven by the rapid growth of Qixia’s diabetes business, which increased by 30.6% year-over-year.In addition, the diagnostics business grew by 2.9% year-on-year, and the medical equipment business grew by 7.6% year-on-year.

In 2020, Abbott's CEOMiles White will officially step down at the end of March, to be succeeded byRobert Ford, President and Chief Operating Officer of Abbott, assumes the role.

It is reported that Abbott will continue its M&A activities in 2020.

Johnson & Johnson Medical entered one of the hottest fields in medical technology this year, inAuris Health and Its Monarch Robot-Assisted Bronchoscopy Platformspent $3.4 billion on, usingVerb Surgical and orthopedic surgery to supplement the robot-assisted general surgery program, and acquire the orthopedic platform。

2019,Johnson & Johnson’s total revenue reached $25.963 billion, a 3.8% year-over-year decline.The primary reason lies in Johnson & Johnson’s continued restructuring of its medical device division, which involved two asset divestitures:Sold its advanced sterilization products business to Fortive for $2.8 billion,and sold Qixia's Lifecan glucose monitoring subsidiary to Platinum Equity for $2.1 billion.

In 2019,Medtronic Achieves Annual Revenue of $30.891 Billion, a 2% Year-over-Year Increase. Mainly attributed to QixiaThe diabetes business and the restorative therapy business experienced significant growth, with increases of 12% and 6%, respectively.。

In August 2019, Medtronic announced a CEO succession plan, stating that Omar Ishrak, Chief Executive Officer of Medtronic, would retire at the end of fiscal year 2020 after nearly nine years at the helm. Geoff Martha, then President of the company’s Restoration Therapies Group (RTG), was appointed to the newly created role of President of Medtronic.

It is reported that in 2020, Medtronic will continue to implement its three core strategies: therapeutic innovation, globalization, and economic value.